Growth equity fund research profile
Creaegis is a Bengaluru-based growth-equity manager backing digitally enabled Indian companies at the late-growth stage. Its public record is strongest around Fund II, with a sector-agnostic technology and digital-transformation thesis across consumer, healthcare, financial services and enterprise technology.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Creaegis Investment Management uses a growth equity; late-stage investments in digitally enabled indian businesses approach across Consumer, financial services, healthcare, technology.
Current evidence
Creaegis led Ema's $77 million Series B announced on September 23, 2026, after leading Emergent's $130 million Series C in July 2026. The two announcements provide current evidence of ongoing growth-equity deployment.
Strategy
Growth equity; late-stage investments in digitally enabled Indian businesses
Sector focus
Consumer, financial services, healthcare, technology
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Creaegis led Ema's $77 million Series B announced on September 23, 2026, after leading Emergent's $130 million Series C in July 2026. The two announcements provide current evidence of ongoing growth-equity deployment.
Investor questions
Creaegis Investment Management is covered in Rupeia's private equity research universe. The current public record describes the strategy as Growth equity; late-stage investments in digitally enabled Indian businesses, with a sector focus of Consumer, financial services, healthcare, technology. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Creaegis Investment Management in the reviewed public sources: GIVA, Medikabazaar, Zopper, Kale Logistics Solutions, Onsurity, Doceree, Haber, Third Wave Coffee, Zolve, Ema, Emergent, Boston Ivy Healthcare Solutions. It does not represent a complete current portfolio unless the manager has published one.
Public evidence documents current investments and follow-on activity in companies including GIVA, Haber, Onsurity, Zolve, Ema and Emergent. Fund-level realised-return metrics are not publicly disclosed. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: Approximately $425 million final close reported for Creaegis Fund II in September 2023; IFC's disclosure describes a $500 million target and an investment capped at 20% of commitments.. Public terms or access information: Growth-stage Category II AIF strategy; IFC describes a target portfolio of 10–15 companies and typical technology-driven consumer, healthcare, financial-services and technology investments. Detailed carry, fee and reserve terms are not publicly disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Prakash Parthasarathy (Managing Partner and CIO); Nitish Bandi (Partner). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Fund-level IRR, DPI and TVPI are not publicly disclosed. India vehicle-level reserve policy and cheque-size data beyond public descriptions are not disclosed..
2026-09-23: Creaegis led Ema's $77 million Series B announced on September 23, 2026, after leading Emergent's $130 million Series C in July 2026. The two announcements provide current evidence of ongoing growth-equity deployment.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.